



Rajasthan Medical Services Corporation Limited

Gandhi Block, Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur-302005 (Raj.)

Phone No: 0141-2228066 , 2228064 Fax No. 0141-2228065 Website: www.rmssc.nic.in

CIN:U24232RJ2011SGC035067 E_mail : edprocurement@gmail.com, and rmssc@nic.in

Ref. No.:- F.02(169)/RMSC/PROCUREMENT/DRUG/NIB-01/2016/156

Dated: 02.02.2016

Corrigendum - 1

Subject:- Extension of last date for Bid submission and Amendments in technical specifications and other conditions of bid document

Ref. - Pre bid meeting dated 08.01.2016 For the Bid reference no F.02(169)/RMSC/PROCUREMENT/DRUG/NIB-01/2015/01 Dated:01.01.2016 (Technical bid opening due on dated - 04.02.2016)

S. No	Existing condition / technical specification/Packing Unit/Quantity (clause no.)	Amended condition / technical specification/ Packing Unit/Quantity.																																				
1.	<p>Date of submission for E-bids reference no F.02(169)/RMSC/PROCUREMENT/DRUG/NIB-01/2015/01 Dated:01.01.2016 is 1.30 PM of 04.02.2016</p> <table border="1"> <tr> <td>Last date and time of submission of online bids</td> <td>04.02.2016 at 1.30 PM</td> </tr> <tr> <td>Date and time of opening of Online technical bids</td> <td>04.02.2016 at 2.30 PM</td> </tr> <tr> <td>EMD, Tender fees, RISL fees through challan</td> <td>03.02.2016</td> </tr> <tr> <td>EMD, Tender fees, RISL fees Physically</td> <td>04.02.2016 at 1.30 PM</td> </tr> </table>	Last date and time of submission of online bids	04.02.2016 at 1.30 PM	Date and time of opening of Online technical bids	04.02.2016 at 2.30 PM	EMD, Tender fees, RISL fees through challan	03.02.2016	EMD, Tender fees, RISL fees Physically	04.02.2016 at 1.30 PM	<p>Date Extended for submission of E-bids reference no F.02(169)/RMSC/PROCUREMENT/DRUG/NIB-01/2016/01 Dated:01.01.2016 is 1.30 PM of 23.02.2016</p> <table border="1"> <tr> <td>Last date and time of submission of online bids</td> <td>23.02.2016 up to 1.30 PM</td> </tr> <tr> <td>Date and time of opening of Online technical bids</td> <td>23.02.2016 at 2.30 PM</td> </tr> <tr> <td>EMD, Tender fees, RISL fees through challan</td> <td>22.02.2016</td> </tr> <tr> <td>EMD, Tender fees, RISL fees Physically</td> <td>23.02.2016 up to 1.30 PM</td> </tr> </table>	Last date and time of submission of online bids	23.02.2016 up to 1.30 PM	Date and time of opening of Online technical bids	23.02.2016 at 2.30 PM	EMD, Tender fees, RISL fees through challan	22.02.2016	EMD, Tender fees, RISL fees Physically	23.02.2016 up to 1.30 PM																				
Last date and time of submission of online bids	04.02.2016 at 1.30 PM																																					
Date and time of opening of Online technical bids	04.02.2016 at 2.30 PM																																					
EMD, Tender fees, RISL fees through challan	03.02.2016																																					
EMD, Tender fees, RISL fees Physically	04.02.2016 at 1.30 PM																																					
Last date and time of submission of online bids	23.02.2016 up to 1.30 PM																																					
Date and time of opening of Online technical bids	23.02.2016 at 2.30 PM																																					
EMD, Tender fees, RISL fees through challan	22.02.2016																																					
EMD, Tender fees, RISL fees Physically	23.02.2016 up to 1.30 PM																																					
2.	<p>Annexure VIII and BoQ</p> <table border="1"> <thead> <tr> <th>S.N o</th> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>212</td> <td>Verapamil Injection IP 2.5 mg/ml</td> </tr> <tr> <td>2</td> <td>229</td> <td>Barium Sulphate Suspension IP 100%</td> </tr> <tr> <td>3</td> <td>347</td> <td>Clomipramine Capsules IP 25 mg</td> </tr> <tr> <td>4</td> <td>522</td> <td>Pyrimethamine and Sulphadoxine Tablets IP (Pyrimethamine 37.5 mg and Sulphadoxine 750 mg)</td> </tr> <tr> <td>5</td> <td>539</td> <td>Bromocriptine Tablets IP 1.25 mg</td> </tr> <tr> <td>6</td> <td>567</td> <td>Permethrin Lotion 1%</td> </tr> <tr> <td>7</td> <td>587</td> <td>Clotrimazole 1% with lignocaine 1% Ear Drops</td> </tr> <tr> <td>8</td> <td>606</td> <td>Testosterone Propionate Injection IP 25 mg/ 1ml</td> </tr> <tr> <td>9</td> <td>609</td> <td>Chlorzoxazone Tablets 250 mg</td> </tr> <tr> <td>10</td> <td>625</td> <td>Nicotinamide Tablets IP 50 mg</td> </tr> <tr> <td>11</td> <td>628</td> <td>Riboflavin Tablets IP 5 mg</td> </tr> </tbody> </table>	S.N o	Code No.	Name of item with specification	1	212	Verapamil Injection IP 2.5 mg/ml	2	229	Barium Sulphate Suspension IP 100%	3	347	Clomipramine Capsules IP 25 mg	4	522	Pyrimethamine and Sulphadoxine Tablets IP (Pyrimethamine 37.5 mg and Sulphadoxine 750 mg)	5	539	Bromocriptine Tablets IP 1.25 mg	6	567	Permethrin Lotion 1%	7	587	Clotrimazole 1% with lignocaine 1% Ear Drops	8	606	Testosterone Propionate Injection IP 25 mg/ 1ml	9	609	Chlorzoxazone Tablets 250 mg	10	625	Nicotinamide Tablets IP 50 mg	11	628	Riboflavin Tablets IP 5 mg	<p>Annexure VIII and BoQ Item with code no 212, 229, 347, 522, 539, 567, 587, 606, 609, 625 and 628 are deleted.</p>
S.N o	Code No.	Name of item with specification																																				
1	212	Verapamil Injection IP 2.5 mg/ml																																				
2	229	Barium Sulphate Suspension IP 100%																																				
3	347	Clomipramine Capsules IP 25 mg																																				
4	522	Pyrimethamine and Sulphadoxine Tablets IP (Pyrimethamine 37.5 mg and Sulphadoxine 750 mg)																																				
5	539	Bromocriptine Tablets IP 1.25 mg																																				
6	567	Permethrin Lotion 1%																																				
7	587	Clotrimazole 1% with lignocaine 1% Ear Drops																																				
8	606	Testosterone Propionate Injection IP 25 mg/ 1ml																																				
9	609	Chlorzoxazone Tablets 250 mg																																				
10	625	Nicotinamide Tablets IP 50 mg																																				
11	628	Riboflavin Tablets IP 5 mg																																				
3.	<p>Clause 2(b) ELIGIBILITY CRITERIA Explanatory Note 1 and Clause 2 (c)</p> <p>Clause 5(m) TECHNICAL BID Explanatory Note 1 if there is no separate legal entity of sister concern</p>	<p>Clause 2(b) ELIGIBILITY CRITERIA Explanatory Note 1 and Clause 2 (c)</p> <p>Clause 5(m) TECHNICAL BID Explanatory Note 1 The condition "if there is no separate legal entity of sister concern" deleted from the bid</p>																																				

Mr

Signature

Signature

4.	<p>Annexure VIII and BoQ</p> <table border="1"> <thead> <tr> <th>S.No</th> <th>Code No.</th> <th>Name of item with specification</th> <th>Shelf Life</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>369</td> <td>Ipratropium Bromide Nebulizer Solution 250 mcg/ml</td> <td>36</td> </tr> <tr> <td>2</td> <td>378</td> <td>Dextrose Injection IP 25 % w/v</td> <td>36</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>S.No</th> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>437</td> <td>Diclofenac Prolonged Release Tablete IP</td> </tr> </tbody> </table>	S.No	Code No.	Name of item with specification	Shelf Life	1	369	Ipratropium Bromide Nebulizer Solution 250 mcg/ml	36	2	378	Dextrose Injection IP 25 % w/v	36	S.No	Code No.	Name of item with specification	1.	437	Diclofenac Prolonged Release Tablete IP	<p>Annexure VIII and BoQ</p> <table border="1"> <thead> <tr> <th>S.No</th> <th>Code No.</th> <th>Name of item with specification</th> <th>Amended Shelf Life</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>369</td> <td>Ipratropium Bromide Nebulizer Solution 250 mcg/ ml</td> <td>24</td> </tr> <tr> <td>2</td> <td>378</td> <td>Dextrose Injection IP 25 % w/v</td> <td>24</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>S.No</th> <th>Code No.</th> <th>Name of item with Amended specification</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>437</td> <td>Diclofenac Prolonged Release Tablet IP 100mg</td> </tr> </tbody> </table>	S.No	Code No.	Name of item with specification	Amended Shelf Life	1	369	Ipratropium Bromide Nebulizer Solution 250 mcg/ ml	24	2	378	Dextrose Injection IP 25 % w/v	24	S.No	Code No.	Name of item with Amended specification	1.	437	Diclofenac Prolonged Release Tablet IP 100mg																								
S.No	Code No.	Name of item with specification	Shelf Life																																																											
1	369	Ipratropium Bromide Nebulizer Solution 250 mcg/ml	36																																																											
2	378	Dextrose Injection IP 25 % w/v	36																																																											
S.No	Code No.	Name of item with specification																																																												
1.	437	Diclofenac Prolonged Release Tablete IP																																																												
S.No	Code No.	Name of item with specification	Amended Shelf Life																																																											
1	369	Ipratropium Bromide Nebulizer Solution 250 mcg/ ml	24																																																											
2	378	Dextrose Injection IP 25 % w/v	24																																																											
S.No	Code No.	Name of item with Amended specification																																																												
1.	437	Diclofenac Prolonged Release Tablet IP 100mg																																																												
5.	<p>Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID Annexure-XV Ref. Clause No. 2 (c)</p> <table border="1"> <thead> <tr> <th>S.No</th> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>223</td> <td>Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg)</td> </tr> <tr> <td>2</td> <td>241</td> <td>Tropicamide Eye Drops IP 1%</td> </tr> <tr> <td>3</td> <td>324</td> <td>Hydroxypropylmethyl cellulose Solution 20 mg/ ml</td> </tr> <tr> <td>4</td> <td>485</td> <td>Sodium Chloride and Dextrose Inj. IP (0.9%+5%)</td> </tr> <tr> <td>5</td> <td>558</td> <td>Betamethasone Dipropionate Cream IP 0.05%</td> </tr> <tr> <td>6</td> <td>559</td> <td>Betamethasone Lotion IP 0.05%</td> </tr> <tr> <td>7</td> <td>568</td> <td>Permethrin Lotion 5%</td> </tr> <tr> <td>8</td> <td>582</td> <td>Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)</td> </tr> <tr> <td>9</td> <td>650</td> <td>Glyceryl Trinitrate Tablets 2.6 mg Controlled Release tablets</td> </tr> </tbody> </table>	S.No	Code No.	Name of item with specification	1	223	Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg)	2	241	Tropicamide Eye Drops IP 1%	3	324	Hydroxypropylmethyl cellulose Solution 20 mg/ ml	4	485	Sodium Chloride and Dextrose Inj. IP (0.9%+5%)	5	558	Betamethasone Dipropionate Cream IP 0.05%	6	559	Betamethasone Lotion IP 0.05%	7	568	Permethrin Lotion 5%	8	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)	9	650	Glyceryl Trinitrate Tablets 2.6 mg Controlled Release tablets	<p>Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID Annexure-XV Ref. Clause No. 2 (c)</p> <table border="1"> <thead> <tr> <th>S.No</th> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>223</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable.</td> </tr> <tr> <td>2</td> <td>241</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable for Product formula, which have at least all the ingredients of RMSC formulation, (quantity may differ) & may have additional ingredients.</td> </tr> <tr> <td>3</td> <td>324</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable.</td> </tr> <tr> <td>4</td> <td>485</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable.</td> </tr> <tr> <td>5</td> <td>558</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable.</td> </tr> <tr> <td>6</td> <td>559</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable.</td> </tr> <tr> <td>7</td> <td>568</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable.</td> </tr> <tr> <td>8</td> <td>582</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable.</td> </tr> <tr> <td>9</td> <td>650</td> <td>Product permission, Market Standing Certificate and Performance Statement of two year acceptable for the company irrespective of plant.</td> </tr> </tbody> </table> <p>However, for all above items, the firm has to submit with bid, the product permission (from the Licensing Authority) same as per bid specifications.</p>	S.No	Code No.	Name of item with specification	1	223	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.	2	241	Product permission, Market Standing Certificate and Performance Statement of two year acceptable for Product formula, which have at least all the ingredients of RMSC formulation, (quantity may differ) & may have additional ingredients.	3	324	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.	4	485	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.	5	558	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.	6	559	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.	7	568	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.	8	582	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.	9	650	Product permission, Market Standing Certificate and Performance Statement of two year acceptable for the company irrespective of plant.
S.No	Code No.	Name of item with specification																																																												
1	223	Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg)																																																												
2	241	Tropicamide Eye Drops IP 1%																																																												
3	324	Hydroxypropylmethyl cellulose Solution 20 mg/ ml																																																												
4	485	Sodium Chloride and Dextrose Inj. IP (0.9%+5%)																																																												
5	558	Betamethasone Dipropionate Cream IP 0.05%																																																												
6	559	Betamethasone Lotion IP 0.05%																																																												
7	568	Permethrin Lotion 5%																																																												
8	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)																																																												
9	650	Glyceryl Trinitrate Tablets 2.6 mg Controlled Release tablets																																																												
S.No	Code No.	Name of item with specification																																																												
1	223	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.																																																												
2	241	Product permission, Market Standing Certificate and Performance Statement of two year acceptable for Product formula, which have at least all the ingredients of RMSC formulation, (quantity may differ) & may have additional ingredients.																																																												
3	324	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.																																																												
4	485	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.																																																												
5	558	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.																																																												
6	559	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.																																																												
7	568	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.																																																												
8	582	Product permission, Market Standing Certificate and Performance Statement of two year acceptable.																																																												
9	650	Product permission, Market Standing Certificate and Performance Statement of two year acceptable for the company irrespective of plant.																																																												
6.	<p>Clause 5(i) TECHNICAL BID</p> <p>WHO-GMP (WHO - Good manufacturing practices Certificate) Certificate issued by the Licensing Authority. The WHO-GMP certificate must not be older than one year from the due date of Bid</p>	<p>Clause 5(i) TECHNICAL BID</p> <p>For item code 398 [Black Disinfectant Fluid (Phenyl) (As per Schedule "O" Grade - III)]</p> <p>GMP (Good manufacturing practices Certificate) Certificate issued by the Licensing Authority. The</p>																																																												

59

[Handwritten marks and signatures]

[Handwritten signature]

submission in the case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of WHO-GMP. The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.

GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of GMP. The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.

Note:-

- It may be noted that if any type of amendments required than further corrigendum will be published and informed.
- Rest terms and conditions will remain the same. It bears approval of MD, RMSC and Purchase committee.

Handwritten initials and marks: "M", "8", a circled "R", and a checkmark.

Handwritten signature
Executive Director (Proc.)
RMSC
Handwritten initials "S"

